Management of castration-resistant, taxane-resistant prostate cancer

Tomasz (Tom) Beer

Management of castration-resistant, taxane-resistant prostate cancer

Research output: Contribution to journal › Article

Abstract

Metastatic castration-resistant prostate cancer that has become resistant to docetaxel chemotherapy represents one of the greatest clinical challenges in the management of this disease. Patients in this situation have an expected median survival that is typically less than 18 months, and they frequently suffer from symptoms related to progressive cancer and/or persistent treatment toxicity. More effective treatments for patients with taxane-resistant disease are desperately needed.

Original language	English (US)
Pages (from-to)	1-5
Number of pages	5
Journal	ONCOLOGY (United States)
Volume	31
Issue number	8
State	Published - Aug 15 2017

ASJC Scopus subject areas

Medicine(all)
Oncology
Cancer Research

Access to Document

Fingerprint Dive into the research topics of 'Management of castration-resistant, taxane-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this

Beer, T. T. (2017). Management of castration-resistant, taxane-resistant prostate cancer. ONCOLOGY (United States), 31(8), 1-5.

@article{8e9c2a972b664f15b20b4c4f615326e9,

title = "Management of castration-resistant, taxane-resistant prostate cancer",

abstract = "Metastatic castration-resistant prostate cancer that has become resistant to docetaxel chemotherapy represents one of the greatest clinical challenges in the management of this disease. Patients in this situation have an expected median survival that is typically less than 18 months, and they frequently suffer from symptoms related to progressive cancer and/or persistent treatment toxicity. More effective treatments for patients with taxane-resistant disease are desperately needed.",

author = "Beer, {Tomasz (Tom)}",

year = "2017",

month = aug,

day = "15",

language = "English (US)",

volume = "31",

pages = "1--5",

journal = "ONCOLOGY (United States)",

issn = "0890-9091",

publisher = "UBM Medica Healthcare Publications",

number = "8",

}

TY - JOUR

T1 - Management of castration-resistant, taxane-resistant prostate cancer

AU - Beer, Tomasz (Tom)

PY - 2017/8/15

Y1 - 2017/8/15

N2 - Metastatic castration-resistant prostate cancer that has become resistant to docetaxel chemotherapy represents one of the greatest clinical challenges in the management of this disease. Patients in this situation have an expected median survival that is typically less than 18 months, and they frequently suffer from symptoms related to progressive cancer and/or persistent treatment toxicity. More effective treatments for patients with taxane-resistant disease are desperately needed.

AB - Metastatic castration-resistant prostate cancer that has become resistant to docetaxel chemotherapy represents one of the greatest clinical challenges in the management of this disease. Patients in this situation have an expected median survival that is typically less than 18 months, and they frequently suffer from symptoms related to progressive cancer and/or persistent treatment toxicity. More effective treatments for patients with taxane-resistant disease are desperately needed.

UR - http://www.scopus.com/inward/record.url?scp=85027701071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027701071&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85027701071

VL - 31

SP - 1

EP - 5

JO - ONCOLOGY (United States)

JF - ONCOLOGY (United States)

SN - 0890-9091

IS - 8

ER -